Cadila Healthcare rose 0.80% to Rs 231.95 after the company said its API manufacturing facility at Dabhasa in Gujarat successfully completed US drug regulator's inspection.
Cadila Healthcare announced hat the US Food and Drug Administration (USFDA) inspected its Active Pharmaceutical Ingredients (API) manufacturing facility at Dabhasa in Gujarat, the group's largest API manufacturing site, from 7th to 11th October 2019. This was a cGMP (current good manufacturing practice) audit and a pre-approval inspection (PAI). At the end of the inspection, no observation (483) was issued. The announcement was made after trading hours on Friday, 11 October 2019.Shares of Cadila Healthcare fell 2.70% in the past two trading sessions to settle at Rs 230.10 on Friday, 11 October 2019, from its close of Rs 236.50 on 9 October 2019.
Meanwhile, the S&P BSE Sensex was up 227 points or 0.59% to 38,353.75.
On the BSE, 16,726 shares were traded in the counter so far compared with average daily volumes of 42,130 shares in the past two weeks. The stock hit an intraday high of Rs 235.30 and an intraday low of Rs 229.65 so far during the day.
The stock hit a 52-week high of Rs 387.50 on 16 October 2018. The stock hit a 52-week low of Rs 206.45 on 22 August 2019.
Cadila Healthcare's consolidated net profit fell 34.1% to Rs 303.60 crore on a 23% surge in net sales to Rs 3,406.20 crore in Q1 June 2019 compared with Q1 June 2018.
Cadila Healthcare is pharmaceutical company.
Powered by Capital Market - Live News